Testimony on Canagliflozin to the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee
January 10, 2012
View as PDF.
View press release
Public Citizen opposes the FDA’s approval of the new diabetes drug canagliflozin because it demonstrates no evidence of any improved clinical outcomes while creating increased risks of dangerous side-effects, including cardiovascular events.